-
CSF proteins of inflammation, proteolysis and lipid transport define preclinical AD and progression to AD dementia in cognitively unimpaired individuals Mol. Neurodegener. (IF 14.9) Pub Date : 2024-11-11 Marta del Campo, Carlos Quesada, Lisa Vermunt, Carel F. W. Peeters, Yanaika S. Hok-A-Hin, Calvin Trieu, Anouk den Braber, Inge M. W. Verberk, Pieter J. Visser, Betty M. Tijms, Wiesje M. van der Flier, Charlotte E. Teunissen
This preclinical AD CSF proteome study identified a panel of 12-CSF markers detecting amyloid positivity and clinical progression to AD with high accuracy; some of these CSF proteins related to immune function, neurotrophic processes, energy metabolism and endolysosomal functioning (e.g., ITGB2, CLEC5A, IGFBP-1, CST3) changed before amyloid positivity is established.
-
Frailty Trajectories Preceding Dementia in the US and UK JAMA Neurol. (IF 20.4) Pub Date : 2024-11-11 David D. Ward, Jonny P. Flint, Thomas J. Littlejohns, Isabelle F. Foote, Marco Canevelli, Lindsay M. K. Wallace, Emily H. Gordon, David J. Llewellyn, Janice M. Ranson, Ruth E. Hubbard, Kenneth Rockwood, Erwin Stolz
ImportanceAn accessible marker of both biological age and dementia risk is crucial to advancing dementia prevention and treatment strategies. Although frailty is a candidate for that role, the nature of the relationship between frailty and dementia is not well understood.ObjectiveTo clarify the temporal relationship between frailty and incident dementia by investigating frailty trajectories in the
-
Epileptiform Electrographic Patterns After Cardiac Arrest JAMA Neurol. (IF 20.4) Pub Date : 2024-11-11 Andrea O. Rossetti, Sarah Benghanem
This Viewpoint challenges conventional clinical practice that eschews pharmacological intervention for comatose patients with epileptiform abnormalities after cardiac arrest using evidence from the Treatment of Electroencephalographic Status Epilepticus after Cardiopulmonary Resuscitation (TELSTAR) trial.
-
The Health Equity Scholars Program: Fostering Culturally Competent and Successful Independent Investigators in Alzheimer's Disease and Related Dementia Research Alzheimers Dement. (IF 13.0) Pub Date : 2024-11-07 Hannatu Amaza, Amber Niay, Mai Seng Thao, Joe Strong, Alyssa Arentoft, Vanessa Guzman, Sid E. O'Bryant, Mike Weiner, Mónica Rivera Mindt, Ozioma C. Okonkwo,
The Health Equity Scholars Program (HESP) addresses the critical need for a diverse, culturally competent workforce to study and treat older adults from underrepresented populations (URPs) with Alzheimer's disease and related dementias (AD/ADRD). The HESP offers tailored mentored training in AD/ADRD research concepts, aiming to develop successful independent researchers. It recruits Scholars from underrepresented
-
Association of amyloid and cardiovascular risk with cognition: Findings from KBASE Alzheimers Dement. (IF 13.0) Pub Date : 2024-11-07 Soumilee Chaudhuri, Desarae A. Dempsey, Yen-Ning Huang, Tamina Park, Sha Cao, Evgeny J. Chumin, Hannah Craft, Paul K. Crane, Shubhabrata Mukherjee, Seo-Eun Choi, Phoebe Scollard, Michael Lee, Connie Nakano, Jesse Mez, Emily H. Trittschuh, Brandon S. Klinedinst, Timothy J. Hohman, Jun-Young Lee, Koung Mi Kang, Chul-Ho Sohn, Yu Kyeong Kim, Dahyun Yi, Min Soo Byun, Shannon L. Risacher, Kwangsik Nho, Andrew
Limited research has explored the effect of cardiovascular risk and amyloid interplay on cognitive decline in East Asians.
-
Dementia risk reduction in the African context: Multi-national implementation of multimodal strategies to promote healthy brain aging in Africa (the Africa-FINGERS project) Alzheimers Dement. (IF 13.0) Pub Date : 2024-11-07 Chinedu T. Udeh-Momoh, Rachel Maina, Udunna C. Anazodo, Rufus Akinyemi, Lukoye Atwoli, Laura Baker, Darina Bassil, Karen Blackmon, Edna Bosire, Gloria Chemutai, Lucia Crivelli, Laz U. Eze, Agustin Ibanez, Dimitra Kafetsouli, Thomas K. Karikari, Linda Khakali, Manasi Kumar, Imre Lengyel, Celeste A. de Jager Loots, Francesca Mangialasche, Sylvia Mbugua, Zul Merali, Michelle Mielke, Cyprian Mostert, Eunice
Dementia prevention in Africa is critically underexplored, despite the continent's high prevalence of modifiable risk factors. With a predominantly young and middle-aged population, Africa presents a prime opportunity to implement evidence-based strategies that could significantly reduce future dementia cases and mitigate its economic impact. The multinational Africa-FINGERS program offers an innovative
-
Global brain activity and its coupling with cerebrospinal fluid flow is related to tau pathology Alzheimers Dement. (IF 13.0) Pub Date : 2024-11-07 Feng Han, JiaQie Lee, Xi Chen, Jacob Ziontz, Tyler Ward, Susan M. Landau, Suzanne L. Baker, Theresa M. Harrison, William J. Jagust
Factors responsible for the deposition of pathological tau in the brain are incompletely understood. This study links macroscale tau deposition in the human brain to cerebrospinal fluid (CSF) flow dynamics using resting-state functional magnetic resonance imaging (rsfMRI).
-
Genome‐wide transcriptome analysis of Aβ deposition on PET in a Korean cohort Alzheimers Dement. (IF 13.0) Pub Date : 2024-11-08 Tamina Park, Jiyun Hwang, Shiwei Liu, Soumilee Chaudhuri, Sang Won Han, Dahyun Yi, Min Soo Byun, Yen‐Ning Huang, Thea Rosewood, Gijung Jung, Min Jeong Kim, Hyejin Ahn, Jun‐Young Lee, Yu Kyeong Kim, MinYoung Cho, Paula J. Bice, Hannah Craft, Shannon L. Risacher, Hongyu Gao, Yunlong Liu, SangYun Kim, Young Ho Park, Dong Young Lee, Andrew J. Saykin, Kwangsik Nho
INTRODUCTIONDespite the recognized importance of including ethnic diversity in Alzheimer's disease (AD) research, substantial knowledge gaps remain, particularly in Asian populations.METHODSRNA sequencing was performed on blood samples from the Korean Brain Aging Study for the Early Diagnosis and Prediction of Alzheimer's Disease (KBASE) to perform differential gene expression (DGE), gene co‐expression
-
Pharmacodynamic effects of semorinemab on plasma and CSF biomarkers of Alzheimer's disease pathophysiology Alzheimers Dement. (IF 13.0) Pub Date : 2024-11-08 Stephen P. Schauer, Balazs Toth, Julie Lee, Lee A. Honigberg, Vidya Ramakrishnan, Jenny Jiang, Gwendlyn Kollmorgen, Anna Bayfield, Norbert Wild, Jennifer Hoffman, Ryan Ceniceros, Michael Dolton, Sandra M. Sanabria Bohórquez, Casper C. Hoogenraad, Kristin R. Wildsmith, Edmond Teng, Cecilia Monteiro, Veronica Anania, Felix L. Yeh
INTRODUCTIONSemorinemab, an anti‐tau monoclonal antibody, was assessed in two Phase II trials for Alzheimer's disease (AD). Plasma and cerebrospinal fluid (CSF) biomarkers provided insights into the drug's potential mechanism of action.METHODSQualified assays were used to measure biomarkers of tau, amyloidosis, glial activity, neuroinflammation, synaptic function, and neurodegeneration from participant
-
Assessing polyomic risk to predict Alzheimer's disease using a machine learning model Alzheimers Dement. (IF 13.0) Pub Date : 2024-11-08 Tiffany Ngai, Julian Willett, Mohammad Waqas, Lucas H. Fishbein, Younjung Choi, Georg Hahn, Kristina Mullin, Christoph Lange, Julian Hecker, Rudolph E. Tanzi, Dmitry Prokopenko
INTRODUCTIONAlzheimer's disease (AD) is the most common form of dementia in the elderly. Given that AD neuropathology begins decades before symptoms, there is a dire need for effective screening tools for early detection of AD to facilitate early intervention.METHODSHere, we used tree‐based and deep learning methods to train polyomic prediction models for AD affection status and age at onset, employing
-
Bridging the gap: unlocking the potential of emerging drug therapies for brain metastasis Brain (IF 10.6) Pub Date : 2024-11-08 Jiatong Ding, Yale Jiang, Ning Jiang, Shujun Xing, Fan Ge, Peiwen Ma, Qiyu Tang, Huilei Miao, Jiawei Zhou, Yuan Fang, Dandan Cui, Dongyan Liu, Yanjie Han, Weijie Yu, Yuning Wang, Guo Zhao, Yuanting Cai, Shuhang Wang, Nan Sun, Ning Li
Brain metastasis (BrM) remains an unmet clinical need in advanced cancers with an increasing incidence and poor prognosis. The limited response to various treatments is mainly derived from the presence of the substantive barrier, blood–brain barrier (BBB) and brain–tumor barrier (BTB), which hinders the access of potentially effective therapeutics to the metastatic tumor of brain. Recently, the understanding
-
Mitochondrial dynamics and bioenergetics in Alzheimer’s induced pluripotent stem cell-derived neurons Brain (IF 10.6) Pub Date : 2024-11-08 Courtney MacMullen, Neelam Sharma, Ronald L Davis
Mitochondrial (MT) dysfunction is a hallmark of Alzheimer’s Disease (AD), but the scope and severity of these specific deficits across forms of AD are not well characterized. We designed a high-throughput, longitudinal, phenotypic assay to track MT dynamics and bioenergetics in glutamatergic iPSC-derived human neurons possessing mutations in presenilin 1 (PSEN1), presenilin 2 (PSEN2) and the amyloid
-
Astroglial reactivity is a key modulator of Alzheimer’s disease pathological progression Brain (IF 10.6) Pub Date : 2024-11-08 Wiesje Pelkmans, Juan Domingo Gispert
This scientific commentary refers to ‘Association of glial fibrillary acid protein, Alzheimer's disease pathology and cognitive decline’ by Peretti et al. (https://doi.org/10.1093/brain/awae211).
-
TMEM106B amyloid filaments in the Biondi bodies of ependymal cells Acta Neuropathol. (IF 9.3) Pub Date : 2024-11-06 Bernardino Ghetti, Manuel Schweighauser, Max H. Jacobsen, Derrick Gray, Mehtap Bacioglu, Alexey G. Murzin, Bradley S. Glazier, Taxiarchis Katsinelos, Ruben Vidal, Kathy L. Newell, Sujuan Gao, Holly J. Garringer, Maria Grazia Spillantini, Sjors H. W. Scheres, Michel Goedert
-
Compartment-specific small non-coding RNA changes and nucleolar defects in human mesial temporal lobe epilepsy Acta Neuropathol. (IF 9.3) Pub Date : 2024-11-07 Vamshidhar R. Vangoor, Giuliano Giuliani, Marina de Wit, Carolina K. Rangel, Morten T. Venø, Joran T. Schulte, Andreia Gomes-Duarte, Ketharini Senthilkumar, Noora Puhakka, Jørgen Kjems, Pierre N. E. de Graan, R. Jeroen Pasterkamp
-
Technology that CARES: Enhancing dementia care through everyday technologies Alzheimers Dement. (IF 13.0) Pub Date : 2024-11-07 Andrew M. Kiselica, Greta E Hermann, Michael K. Scullin, Jared F. Benge
“Everyday technologies” have long been suggested as digital tools to improve life for and enhance care of persons with Alzheimer's disease and related dementias (ADRD). Within this realm, there is a need to balance potential drawbacks of technologies with their ability to positively impact patient and care partner centered outcomes. To facilitate this goal, we endeavored to provide a common language
-
Perivascular space dysfunction in cerebral small vessel disease is related to neuroinflammation Brain (IF 10.6) Pub Date : 2024-11-07 Hui Hong, Dan Tozer, Yutong Chen, Robin Brown, Audrey Low, Hugh S Markus
Enlarged perivascular spaces are a feature of cerebral small vessel disease, and it has been hypothesized that they may reflect impaired glymphatic drainage. The mechanisms underlying perivascular spaces enlargement are not fully understood, but both increased inflammation and blood brain barrier permeability have been hypothesized to play a role. We investigated the relationship between perivascular
-
Potential Disease‐Modifying Effects of Ganglioside GM1 Pulse Treatment on Spinocerebellar Ataxia Type 3, a Parallel‐Group, Double‐Blind, Randomized, Controlled Trial Mov. Disord. (IF 7.4) Pub Date : 2024-11-07 Yong‐Kang Chen, Hai‐Yan Tian, Qing‐Yong Zhu, Rui Zhang, Dong‐Xiao Liang, Jiu‐Qi Wang, Ren‐Yi Feng, Chi Qin, Ming‐Ming Ma, Hong Jiang, Bei‐Sha Tang, Xue‐Bing Ding, Xue‐Jing Wang
BackgroundSpinocerebellar ataxia type 3 (SCA3) is an autosomal dominant inherited neurodegenerative disorder for which there is currently no cure, nor effective treatment strategy.ObjectiveOur aim was to investigate the safety and efficacy of high‐dose ganglioside GM1 (ganglioside‐monosialic acid) pulse treatment in patients with SCA3.MethodsPatients were randomly allocated to receive either high‐dose
-
Mental health disorders before, during and after the COVID-19 pandemic: a nationwide study Brain (IF 10.6) Pub Date : 2024-11-06 Clara S Grønkjær, Rune H B Christensen, Daniel Kondziella, Michael E Benros
The COVID-19 pandemic and lockdowns prompted a major concern for mental health effects. Comprehensive nationwide studies are lacking on the indirect effect of the COVID-19 pandemic on the population’s mental health. We aimed to determine whether the COVID-19 pandemic and lockdowns affected mental health service usage, suicide attempts, and suicides. This comprehensive nationwide register-linked study
-
Tau, synapse loss and gliosis progress in an Alzheimer’s mouse model after amyloid-β immunotherapy Brain (IF 10.6) Pub Date : 2024-11-06 Lindsay A Welikovitch, Anastasie Mate de Gerando, Anita Khasnavis, Harshil Bhavsar, Jonah C Meltzer, Luc Buée, Lori B Chibnik, Thierry Bussiere, Bradley T Hyman
While preclinical studies assessing drugs for Alzheimer’s disease (AD) are conducted in animal models that usually display only one neuropathological feature of AD, patients present with a complex combination of comorbidities and neuropathologies. Importantly, it is well-established that amyloid (Aβ) plaque and tau tangle accumulation interact in a phase-dependent manner, making it difficult to predict
-
Focal brain administration of antiseizure medications improves outcomes and reduces side effects. Brain (IF 10.6) Pub Date : 2024-11-06 Annamaria Vezzani
-
Phase 2b program with sonlicromanol in patients with mitochondrial disease due to m.3243A>G mutation. Brain (IF 10.6) Pub Date : 2024-11-06 Jan Smeitink,Just van Es,Brigitte Bosman,Mirian C H Janssen,Thomas Klopstock,Grainne Gorman,John Vissing,Gerrit Ruiterkamp,Chris J Edgar,Evertine J Abbink,Rob van Maanen,Oksana Pogoryelova,Claudia Stendel,Almut Bischoff,Ivan Karin,Mahtab Munshi,Anne Kümmel,Lydia Burgert,Christianne Verhaak,Herma Renkema
Mitochondrial disease is a group of rare conditions, with no approved treatment to date, except for Leber hereditary optic neuropathy. Therapeutic options to alleviate the symptoms of mitochondrial disease are urgently needed. Sonlicromanol is a promising candidate, as it positively alters the key metabolic and inflammatory pathways associated with mitochondrial disease. Sonlicromanol is a reductive
-
Association of Sleep Disturbances With Prevalent and Incident Motoric Cognitive Risk Syndrome in Community-Residing Older Adults. Neurology (IF 7.7) Pub Date : 2024-11-06 Victoire Leroy,Emmeline Ayers,Dristi Adhikari,Joe Verghese
BACKGROUND AND OBJECTIVES There is growing evidence that sleep disturbances are associated with cognitive impairment risk, but their association with the incidence of motoric cognitive risk syndrome (MCR)-a predementia syndrome characterized by slow gait speed and cognitive complaints-is unknown. We aimed to examine the association of sleep disturbances, overall and specific subtypes, with (1) incident
-
Health-Related Behaviors and Risk of Common Age-Related Brain Diseases Across Severities of Genetic Risk. Neurology (IF 7.7) Pub Date : 2024-11-06 Sandro Marini,Tamara N Kimball,Ernst Mayerhofer,Reinier W P Tack,Jasper R Senff,Savvina Prapiadou,Cyprien A Rivier,Jonathan Duskin,Christina Kourkoulis,Guido J Falcone,Nirupama Yechoor,Rudolph E Tanzi,Jonathan Rosand,Sanjula Singh,Livia Parodi,Christopher D Anderson
BACKGROUND AND OBJECTIVES The 21-point Brain Care Score (BCS) is an index that ranks behaviors and clinical measurements with the aim of encouraging lifestyle adjustments to lower the incidence of age-related brain disease, including stroke, late-life depression (LLD), and dementia. A higher BCS at baseline is associated with a lower risk of these outcomes. We aimed to investigate whether the associations
-
Identification of Novel Genetic Loci Affecting Age at Onset of Parkinson's Disease: A Genome‐wide Association Study Mov. Disord. (IF 7.4) Pub Date : 2024-11-06 Yun Su Hwang, Sungyang Jo, Seung Hyun Lee, Kye Won Park, Eunsoon Shin, YoonGi Park, Yunji Seo, Kyum‐Yil Kwon, Jae Seung Kim, Sang Ryong Jeon, Jae‐Hong Lee, Sun Ju Chung
BackgroundThe age at onset (AAO) of Parkinson's disease (PD) varies widely among individuals and significantly influences disease progression and prognosis. However, few genome‐wide association studies (GWASs) have investigated genetic variants determining AAO, particularly in East Asian populations.ObjectivesTo identify single‐nucleotide polymorphisms (SNPs) affecting AAO of PD in Korean patients
-
Smaller cingulate grey matter mediates the association between dual-task gait and incident dementia Brain (IF 10.6) Pub Date : 2024-11-05 Pauline Ali, Frederico Pieruccini-Faria, Cédric Annweiler, Mickaël Dinomais, Surim Son, Scott K Wilson, Richard Camicioli, Susan Muir-Hunter, Robert Bartha, Manuel Montero-Odasso
Individuals with mild cognitive impairment that have high dual-task gait cost (≥20% slowing in gait speed while performing a cognitive brain demanding task), are three-fold more likely to progress to dementia. However, the cortical regions that may explain this association are unknown, which may identify potentially treatable areas. The aim of the current study is to investigate whether brain grey
-
Natural history of Becker muscular dystrophy: DMD gene mutations predict clinical severity Brain (IF 10.6) Pub Date : 2024-11-05 Domenico Gorgoglione, Daniele Sabbatini, Pietro Riguzzi, Giuliana Capece, Marika Pane, Serenella Servidei, Marta Briganti, Cristina Sancricca, Fabio Bruschi, Anna Ardissone, Riccardo Masson, Annamaria Gallone, Lorenzo Maggi, Esther Picillo, Luisa Politano, Angela Petrosino, Sara Vianello, Martina Penzo, Matteo Villa, Maria Sframeli, Cosimo Allegra, Andrea Barp, Alessandra Di Bari, Francesca Salmin
Background Becker muscular dystrophy (BMD) is an X-linked neuromuscular disease due to mutations in the DMD gene, leading to a deficient and less functional dystrophin mainly in skeletal and cardiac muscle. Understanding the natural history of BMD is crucial for optimizing patient care and developing targeted treatments. Materials and methods Retrospective data were collected from 943 patients diagnosed
-
Association of Cerebrovascular Reactivity With 1-Year Imaging and Clinical Outcomes in Small Vessel Disease: An Observational Cohort Study. Neurology (IF 7.7) Pub Date : 2024-11-05 Emilie Sleight,Michael S Stringer,Una Clancy,Carmen Arteaga-Reyes,Daniela Jaime Garcia,Angela C C Jochems,Stewart Wiseman,Maria Valdes Hernandez,Francesca M Chappell,Fergus N Doubal,Ian Marshall,Michael J Thrippleton,Joanna M Wardlaw
BACKGROUND AND OBJECTIVES In patients with cerebral small vessel disease (SVD), impaired cerebrovascular reactivity (CVR) is related to worse concurrent SVD burden, but less is known about cerebrovascular reactivity and long-term SVD lesion progression and clinical outcomes. We investigated associations between cerebrovascular reactivity and 1-year progression of SVD features and clinical outcomes
-
Multimodal Assessment of the Origin of Myoclonus in Lance-Adams Syndrome. Neurology (IF 7.7) Pub Date : 2024-11-05 Geoffroy Vellieux,Emmanuelle Apartis,Paul Baudin,Manuel Alejandro Del Río Quiñones,Diane Villemonte de la Clergerie,Aurélie Kas,Vincent Navarro,
BACKGROUND AND OBJECTIVES Lance-Adams syndrome (LAS), or chronic posthypoxic myoclonus, is a long-term disabling neurologic disorder occurring in survivors of anoxia. The cortical or subcortical origin of this myoclonus is unclear. We aimed to identify the neuroanatomical origin of myoclonus in LAS. METHODS We conducted a cross-sectional study and investigated patients diagnosed with LAS from the Department
-
Lance-Adams Syndrome: It Really Comes From the Cortex! Neurology (IF 7.7) Pub Date : 2024-11-05 Jonathan C van Zijl,Martijn Beudel
-
Optimizing Anti-Myelin-Associated Glycoprotein and IgM-Gammopathy Testing for Neuropathy Treatment Evaluation. Neurology (IF 7.7) Pub Date : 2024-11-05 Christopher J Klein,James D Triplett,David L Murray,Amy P Gorsh,Shahar Shelly,Divyanshu Dubey,Marcus V Pinto,Stephen M Ansell,Michael P Skolka,Grace Swart,Michelle L Mauermann,John R Mills
BACKGROUND AND OBJECTIVES Patients with typical anti-myelin-associated glycoprotein (anti-MAG) neuropathy have IgM-gammopathy, mimic distal chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), and are treatment resistant. Anti-MAG patients go unrecognized when IgM-gammopathy is undetected or with atypical phenotypes. We investigated an optimal anti-MAG titration cutoff for excluding CIDP
-
Insulin Resistance Is a Modifying Factor for Parkinson's Disease Mov. Disord. (IF 7.4) Pub Date : 2024-11-05 Alise Zagare, Ahmed Hemedan, Catarina Almeida, Daniela Frangenberg, Gemma Gomez‐Giro, Paul Antony, Rashi Halder, Rejko Krüger, Enrico Glaab, Marek Ostaszewski, Giuseppe Arena, Jens C. Schwamborn
BackgroundParkinson's disease (PD) is the second most common, and the fastest‐growing neurodegenerative disorder with unclear etiology in most cases. Therefore, the identification of non‐genetic risk factors for PD pathology is crucial to develop effective preventative or therapeutic strategies. An increasing number of evidence suggests that central insulin resistance might have an essential role in
-
Parkinson disease therapy: current strategies and future research priorities Nat. Rev. Neurol. (IF 28.2) Pub Date : 2024-11-04 Fabrizio Stocchi, Daniele Bravi, Aron Emmi, Angelo Antonini
-
Deferiprone in Alzheimer Disease JAMA Neurol. (IF 20.4) Pub Date : 2024-11-04 Scott Ayton, David Barton, Bruce Brew, Amy Brodtmann, Roger Clarnette, Patricia Desmond, David Devos, Kathryn A. Ellis, Amir Fazlollahi, Caroline Fradette, Anita M. Y. Goh, Pawel Kalinowski, Christopher Kyndt, Rosalyn Lai, Yen Ying Lim, Paul Maruff, Terence J. O’Brien, Christopher Rowe, Olivier Salvado, Peter W. Schofield, Michael Spino, Fernando Tricta, Aaron Wagen, Robert Williams, Michael Woodward
ImportanceInterventions that substantially slow neurodegeneration are needed to address the growing burden of Alzheimer disease (AD) to societies worldwide. Elevated brain iron observed in AD has been associated with accelerated cognitive decline and may be a tractable drug target.ObjectiveTo investigate whether the brain-permeable iron chelator deferiprone slows cognitive decline in people with AD
-
Remembering the Physician’s Humanity—Physicians Are Humans Too JAMA Neurol. (IF 20.4) Pub Date : 2024-11-04 Noriko Anderson
This essay describes the microaggressions and burnout faced by physicians and the importance of boundaries to preserve physicians’ humanity and well-being.
-
Clinical and Radiographic Improvement Following Steroid Therapy in Subacute Post-Traumatic Ascending Myelopathy. Neurology (IF 7.7) Pub Date : 2024-11-04 Olumide Emmanuel Adegunna,Anuj Rastogi,Nathan Chan Smyth,Daniel M Mandell,Alfonso Fasano
-
Epidemiologic Study of Myasthenia Gravis in the Elderly US Population: A Longitudinal Analysis of the Medicare Claims Database, 2006-2019. Neurology (IF 7.7) Pub Date : 2024-11-04 David Bruckman,Ikjae Lee,Jesse D Schold,Benjamin R Claytor,Nicholas J Silvestri,Michael K Hehir,Yuebing Li
BACKGROUND AND OBJECTIVES Epidemiologic studies suggest increasing incidence and prevalence of myasthenia gravis (MG) among the elderly population outside the United States. We aimed to provide an estimation of MG incidence and prevalence and their trend among the Medicare Fee-For-Service (FFS)-covered elderly US population. METHODS We performed a retrospective longitudinal study using Medicare claims
-
Disentangling Neurodegeneration From Aging in Multiple Sclerosis Using Deep Learning: The Brain-Predicted Disease Duration Gap. Neurology (IF 7.7) Pub Date : 2024-11-04 Giuseppe Pontillo,Ferran Prados,Jordan Colman,Baris Kanber,Omar Abdel-Mannan,Sarmad Al-Araji,Barbara Bellenberg,Alessia Bianchi,Alvino Bisecco,Wallace J Brownlee,Arturo Brunetti,Alessandro Cagol,Massimiliano Calabrese,Marco Castellaro,Ronja Christensen,Sirio Cocozza,Elisa Colato,Sara Collorone,Rosa Cortese,Nicola De Stefano,Christian Enzinger,Massimo Filippi,Michael A Foster,Antonio Gallo,Claudio Gasperini
BACKGROUND AND OBJECTIVES Disentangling brain aging from disease-related neurodegeneration in patients with multiple sclerosis (PwMS) is increasingly topical. The brain-age paradigm offers a window into this problem but may miss disease-specific effects. In this study, we investigated whether a disease-specific model might complement the brain-age gap (BAG) by capturing aspects unique to MS. METHODS
-
Lumipulse-Measured Cerebrospinal Fluid Biomarkers for the Early Detection of Alzheimer Disease. Neurology (IF 7.7) Pub Date : 2024-11-04 Michelle Safransky,Jenna R Groh,Kaj Blennow,Henrik Zetterberg,Yorghos Tripodis,Brett Martin,Jason Weller,Breton M Asken,Gil D Rabinovici,Wendy Wei Qiao Qiu,Ann C McKee,Thor D Stein,Jesse Mez,Rachel L Henson,Justin Long,John C Morris,Richard J Perrin,Suzanne E Schindler,Michael L Alosco
BACKGROUND AND OBJECTIVES CSF biomarkers of Aβ42 and phosphorylated tau (p-tau181) are used clinically for the detection of Alzheimer disease (AD) pathology during life. CSF biomarker validation studies have largely used clinical diagnoses and/or amyloid PET imaging as the reference standard. The few existing CSF-to-autopsy studies have been restricted to late-stage AD. This CSF-to-autopsy study investigated
-
Teaching NeuroImage: Use of Arterial Spin Labeling to Differentiate Ictal Phenomenon From Tumor Progression in Grade 3 Astrocytoma. Neurology (IF 7.7) Pub Date : 2024-11-04 Anza Zahid,Nithisha Thatikonda,Prachi Dubey,Ivo W Tremont-Lukats
-
Teaching Video NeuroImage: Noogenic Epilepsy With Orofacial Reflex Myoclonus: A Rare Distinct Electroclinical Syndrome. Neurology (IF 7.7) Pub Date : 2024-11-04 Jayakumari Nandana,Karamala Yalapalli Manisha,Prasannakumar Surabhi,Surendran Veena,Kiren George Koshy,Ramshekhar N Menon,Ashalatha Radhakrishnan
-
Chronic Musculoskeletal Pain and Risk of Incident Parkinson's Disease: A 13-Year Longitudinal Study. Mov. Disord. (IF 7.4) Pub Date : 2024-11-02 Fatemeh Vazirian,Jing Tian,Jane Alty,Dawn Aitken,Michele L Callisaya,Flavia Cicuttini,Graeme Jones,Feng Pan
BACKGROUND Chronic musculoskeletal pain often co-occurs with Parkinson's disease (PD); however, whether individuals with chronic pain have a higher risk of developing PD is unclear. OBJECTIVES To investigate the associations between chronic pain and incident risk of three neurodegenerative parkinsonism categories including PD, multiple system atrophy (MSA), and progressive supranuclear palsy (PSP)
-
Focused Ultrasound Pallidothalamic Tractotomy in Cervical Dystonia: A Pilot Study Mov. Disord. (IF 7.4) Pub Date : 2024-11-02 Shiro Horisawa, Ryo Saito, Bohui Qian, Hiroki Hori, Kilsoo Kim, Masato Murakami, Toru Kakegawa, Keiichi Abe, Atsushi Fukui, Kotaro Kohara, Mutsumi Iijima, Takakazu Kawamata, Takaomi Taira
BackgroundNo clinical trials have been reported on the use of focused ultrasound (FUS) for treating cervical dystonia.ObjectiveWe aimed to confirm the efficacy and safety of FUS pallidothalamic tractotomy for cervical dystonia.MethodsThis was a prospective, open‐label, non‐controlled pilot study. The primary outcome was defined as a change in the score for the Toronto Western Spasmodic Torticollis
-
Cerebellar Transcranial Direct Current Stimulation in the Cerebellar Cognitive Affective Syndrome: A Randomized, Double‐Blind, Sham‐Controlled Trial Mov. Disord. (IF 7.4) Pub Date : 2024-11-02 Stacha F.I. Reumers, Roderick P.P.W.M. Maas, Dennis J.L.G. Schutter, Steven Teerenstra, Roy P.C. Kessels, Frank‐Erik de Leeuw, Bart P.C. van de Warrenburg
BackgroundThe cerebellar cognitive affective syndrome (CCAS) encompasses cognitive and affective symptoms in patients with cerebellar disorders, for which no proven treatment is available.ObjectivesOur primary objective was to study the effect of cerebellar anodal transcranial direct current stimulation (tDCS) on cognitive performance in CCAS patients. Secondary effects on ataxia severity, mood, and
-
Alzheimer Disease as a Clinical-Biological Construct—An International Working Group Recommendation JAMA Neurol. (IF 20.4) Pub Date : 2024-11-01 Bruno Dubois, Nicolas Villain, Lon Schneider, Nick Fox, Noll Campbell, Douglas Galasko, Miia Kivipelto, Frank Jessen, Bernard Hanseeuw, Mercè Boada, Frederik Barkhof, Agneta Nordberg, Lutz Froelich, Gunhild Waldemar, Kristian Steen Frederiksen, Alessandro Padovani, Vincent Planche, Christopher Rowe, Alexandre Bejanin, Agustin Ibanez, Stefano Cappa, Paulo Caramelli, Ricardo Nitrini, Ricardo Allegri
ImportanceSince 2018, a movement has emerged to define Alzheimer disease (AD) as a purely biological entity based on biomarker findings. The recent revision of the Alzheimer Association (AA) criteria for AD furthers this direction. However, concerns about a purely biological definition of AD being applied clinically, the understanding of AD by society at large, and the translation of blood-based biomarkers
-
The Parkinson's disease DJ-1/PARK7 gene controls peripheral neuronal excitability and painful neuropathy Brain (IF 10.6) Pub Date : 2024-11-01 Sang Hoon Lee, Raquel Tonello, Kihwan Lee, Jueun Roh, Arthur Silveira Prudente, Yong Ho Kim, Chul-Kyu Park, Temugin Berta
Parkinson's disease is a progressive neurodegenerative disease with well-documented motor symptoms as well as less recognised, but significant, non-motor symptoms. These non-motor symptoms include prodromal pain and peripheral neuropathy, the causes of which are unknown. We investigated the role of DJ-1/PARK7, a Parkinson's disease-associated gene, in prodromal pain and peripheral neuropathy. Using
-
Skin Biopsy Detection of Phosphorylated α‐Synuclein in Patients of Bullous Pemphigoid with or without Parkinson's Disease Mov. Disord. (IF 7.4) Pub Date : 2024-11-01 Shan Cao, Xiang Fang, Jianwen Wang, Yonghu Sun, Furen Zhang
BackgroundHigh positivity rate of skin phosphorylated α‐synuclein (P‐SYN) was observed in Parkinson's disease (PD). Bullous pemphigoid (BP) is one of the most common autoimmune skin diseases associated with PD.ObjectivesOur aim was to investigate whether BP patients might be a targeted risk population for the screening of skin P‐SYN.MethodsSkin P‐SYN expression was evaluated by immunohistochemistry
-
Effects of brain microRNAs in cognitive trajectory and Alzheimer’s disease Acta Neuropathol. (IF 9.3) Pub Date : 2024-10-30 Selina M. Vattathil, Sarah Sze Min Tan, Paul J. Kim, David A. Bennett, Julie A. Schneider, Aliza P. Wingo, Thomas S. Wingo
-
Proteomic analysis of APOEε4 carriers implicates lipid metabolism, complement and lymphocyte signaling in cognitive resilience Mol. Neurodegener. (IF 14.9) Pub Date : 2024-10-31 Keenan A. Walker, Yang An, Abhay Moghekar, Ruin Moaddel, Michael R. Duggan, Zhongsheng Peng, Qu Tian, Luke C. Pilling, Shannon M. Drouin, Mark A. Espeland, Stephen R Rapp, Kathleen M Hayden, Aladdin H. Shadyab, Ramon Casanova, Madhav Thambisetty, Peter R. Rapp, Dimitrios Kapogiannis, Luigi Ferrucci, Susan M. Resnick
Apolipoprotein E (APOE) ε4 allele is the strongest genetic risk factor for late onset Alzheimer’s disease (AD). This case-cohort study used targeted plasma biomarkers and large-scale proteomics to examine the biological mechanisms that allow some APOEε4 carriers to maintain normal cognitive functioning in older adulthood. APOEε4 carriers and APOEε3 homozygotes enrolled in the Women’s Health Initiative
-
Nifuroxazide rescues the deleterious effects due to CHCHD10-associated MICOS defects in disease models Brain (IF 10.6) Pub Date : 2024-10-31 Baptiste Ropert, Sylvie Bannwarth, Emmanuelle C Genin, Loan Vaillant-Beuchot, Sandra Lacas-Gervais, Blandine Madji Hounoum, Aurore Bernardin, Nhu Dinh, Alessandra Mauri-Crouzet, Marc-Alexandre D’Elia, Gaelle Augé, Françoise Lespinasse, Audrey Di Giorgio, Willian Meira, Nathalie Bonnefoy, Laurent Monassier, Manuel Schiff, Laila Sago, Devrim Kilinc, Frédéric Brau, Virginie Redeker, Delphine Bohl, Déborah
The identification of a point mutation (p.Ser59Leu) in the CHCHD10 gene was the first genetic evidence that mitochondrial dysfunction can trigger motor neuron disease. Since then, we have shown that this mutation leads to the disorganization of the MItochondrial contact site and Cristae Organizing System (MICOS) complex that maintains the mitochondrial cristae structure. Here, we generated yeast mutant
-
Cerebral Amyloid Angiopathy, Dementia, and Alzheimer Neuropathologic Changes: Findings From the ACT Autopsy Cohort. Neurology (IF 7.7) Pub Date : 2024-10-31 Mo-Kyung Sin,Yan Cheng,Ali Ahmed,Jeffrey M Roseman,N Maritza Dowling,Edward Zamrini
BACKGROUND AND OBJECTIVES Cerebral amyloid angiopathy (CAA) is common in older adults and is associated with dementia. Less is known whether this association is mediated by Alzheimer disease (AD) neuropathologic changes, the examination of which was the objective of this study. METHODS This was a retrospective cross-sectional examination of the Kaiser Permanente Washington database of the Adult Changes
-
Diagnosis of Incident Cancer After Cryptogenic Stroke: An Exploratory Analysis of the ARCADIA Randomized Trial. Neurology (IF 7.7) Pub Date : 2024-10-31 Babak B Navi,Cenai Zhang,Benjamin R Miller,Anokhi Pawar,Mary Cushman,Scott E Kasner,David Tirschwell,W T Longstreth,Richard Kronmal,Jordan Elm,Richard M Zweifler,Joseph Tarsia,Joseph P Broderick,David J Gladstone,Morin Beyeler,Hooman Kamel,Mitchell S V Elkind,Christopher Streib
OBJECTIVES The objective of this study was to estimate the incidence, timing, and type of new cancer diagnosis among patients with cryptogenic stroke. METHODS We used data from the ARCADIA trial, which enrolled patients with cryptogenic stroke and atrial cardiopathy. Participants were prospectively followed, and serious adverse events were assessed every 3 months or sooner if investigators were alerted
-
MRI-Based Prediction of Macrovascular Causes of Intracerebral Hemorrhage: The MACRO Score. Neurology (IF 7.7) Pub Date : 2024-10-31 Simon Fandler-Höfler,Gareth Ambler,Martina B Goeldlin,Lena Obergottsberger,Gerit Wünsch,Markus Kneihsl,Wenpeng Zhang,Yang Du,Martina Locatelli,Hatice Ozkan,Philip S Nash,Oliver Nistl,Larysa Panteleienko,Rom Mendel,Kitti Thiankhaw,Robert J Simister,Hans Rolf Jäger,Christian Enzinger,David J Seiffge,Thomas Gattringer,David J Werring
BACKGROUND AND OBJECTIVES Although most spontaneous intracerebral hemorrhages (ICHs) are due to cerebral small vessel diseases (SVDs), between 1 in 7 and 1 in 10 are due to a macrovascular cause. Rapid diagnosis has important therapeutic and prognostic implications but sometimes requires digital subtraction angiography (DSA), an invasive procedure which cannot be performed in all patients. MRI provides
-
Advancing Parkinson's Disease Research in Africa: A Strategic Training Framework of the Global Parkinson's Genetics Program. Mov. Disord. (IF 7.4) Pub Date : 2024-10-31 Kathryn Step,Esraa Eltaraifee,Inas Elsayed,Nomena Rasaholiarison,Njideka Okubadejo,Richard Walker,Wael Mohamed,Mie Rizig,Sara Bandres-Ciga,Alastair J Noyce,Sumit Dey,,Soraya Bardien,Maria Teresa Periñan
-
Comprehensive mapping of synaptic vesicle protein 2A (SV2A) in health and neurodegenerative diseases: a comparative analysis with synaptophysin and ground truth for PET-imaging interpretation Acta Neuropathol. (IF 9.3) Pub Date : 2024-10-30 Mahsa Shanaki Bavarsad, Salvatore Spina, Abby Oehler, Isabel E. Allen, Claudia K. Suemoto, Renata E. P. Leite, William S. Seeley, Ari Green, William Jagust, Gil D. Rabinovici, Lea T. Grinberg
-
SV2A PET shows hippocampal synaptic loss in cognitively unimpaired APOE ε4/ε4 homozygotes Alzheimers Dement. (IF 13.0) Pub Date : 2024-10-30 Anniina Snellman, Jouni Tuisku, Mikko Koivumäki, Saara Wahlroos, Richard Aarnio, Johan Rajander, Mira Karrasch, Laura L. Ekblad, Juha O. Rinne
INTRODUCTIONWe investigated hippocampal synaptic density using synaptic vesicle 2A positron emission tomography (PET), and its association with amyloid beta (Aβ) and cognitive performance in healthy apolipoprotein E (APOE) ε4 carriers.METHODSSynaptic density was assessed in 46 individuals (APOE ε4/ε4 n = 14; APOE ε3/ε4 n = 16; APOE ε3/ε3 n = 16) with [11C]UCB‐J‐PET standardized uptake value ratios
-
Teaching NeuroImage: Superficial Siderosis in Marfan Syndrome. Neurology (IF 7.7) Pub Date : 2024-10-30 João Cláudio Urbano,Adalberto Studart-Neto,Rodrigo H Mendonça,Eduardo G Mutarelli,Cristiana Borges Pereira
-
Prevalence of, and Disability Due to, Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder in Japan by the Fifth Nationwide Survey. Neurology (IF 7.7) Pub Date : 2024-10-30 Mitsuru Watanabe,Noriko Isobe,Masaaki Niino,Ichiro Nakashima,Takuya Matsushita,Yasunari Sakai,Jin Nakahara,Izumi Kawachi,Hirofumi Ochi,Yuji Nakatsuji,Yosikazu Nakamura,Koshi Nakamura,Kiyomi Sakata,Makoto Matsui,Satoshi Kuwabara,Jun-Ichi Kira,
BACKGROUND AND OBJECTIVES All 4 previous nationwide surveys of multiple sclerosis (MS) in Japan were conducted before the discovery of anti-aquaporin-4 (AQP4) antibodies; thus, neuromyelitis optica spectrum disorder (NMOSD) was included in MS, as optic-spinal MS. We aimed to clarify the epidemiologic features and trends of MS and NMOSD in Japan separately using a fifth nationwide survey. METHODS The
-
Immune-Mediated Megaconial Myopathy: A Novel Subtype of Autoimmune Myopathy. Neurology (IF 7.7) Pub Date : 2024-10-30 Ashley R Santilli,Oliver Ni,Margherita Milone,Duygu Selcen,Anahit C Mehrabyan,Arjun Seth,Christine Hsieh,Wasim F Raslan,Moayd M Alkhalifah,Raed M Alenezi,Stefan Nicolau,Pannathat Soontrapa,Teerin Liewluck
OBJECTIVES To describe a novel subtype of autoimmune myopathy, immune-mediated megaconial myopathy (IMMM), myopathologically characterized by giant mitochondria (megaconia). METHODS In this case series, we reviewed the Mayo Clinic Muscle Pathology database, between 2018 and 2023, to identify patients with megaconial pathology, subacute progressive weakness, and hyperCKemia, clinically resembling myositis
-
Costs Are Still on the Rise for Commonly Prescribed Branded Neurologic Medications. Neurology (IF 7.7) Pub Date : 2024-10-30 Amanda V Gusovsky,Chun Chieh Lin,Kevin Kerber,Evan L Reynolds,Brian C Callaghan,James F Burke
OBJECTIVES To observe medication cost trends for 5 common neurologic conditions. METHODS We quantified annual out-of-pocket (OOP) and total medication costs for patients seen by a neurologist with epilepsy, multiple sclerosis (MS), Parkinson disease (PD), peripheral neuropathy (PN), and dementia/Alzheimer's disease in a commercial claims database cross-sectionally from 2012 to 2021. RESULTS We identified